Why Established Deposits Are the Hardest Problem in ATTR-CM

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressively fatal restrictive cardiomyopathy in which misfolded TTR fibrils accumulate in the cardiac interstitium, producing ventricular wall thickening, diastolic dysfunction, and heart failure with preserved ejection fraction. The TTR protein circulates as a tetramer; dissociation into monomers is the rate-limiting step that enables amyloidogenic misfolding and fibril nucleation. Tafamidis — the only FDA-approved treatment for ATTR-CM — stabilizes the native tetramer to slow this process, but it does not address fibrils already deposited in cardiac tissue.

Amyloid fibrils exert cardiac damage through two mechanistically distinct pathways. The first is mechanical infiltration of the myocardium, disrupting cardiomyocyte architecture and compliance. The second is direct proteotoxicity from prefibrillar and oligomeric species, causing mitochondrial dysfunction, reactive oxygen species generation, and metabolic impairment. Research from Oak Ridge National Laboratory demonstrated that λ6 light chain fibrils at nanomolar concentrations decrease NAD(P)H-dependent oxidoreductase activity and increase oxygen consumption in human cardiomyocytes without causing cell death — establishing a metabolic toxicity mechanism that is independent of bulk fibril mass.

Fibril structural resistance compounds the clearance challenge. Cryo-EM data from Heidelberg University Hospital reveal that somatic hypermutations and post-translational modifications — including disulfide bonds, N-glycosylation, and pyroglutamylation — structurally stabilize λ1-AL fibrils against proteolysis, explaining their persistence in cardiac tissue. This structural resilience underpins the failure of endogenous clearance mechanisms and motivates the antibody-based depletion strategies now generating active patent filings. According to WHO, rare cardiac diseases including amyloidosis represent a growing global burden as population ageing increases disease prevalence.

The Antibody Modalities Competing to Clear Cardiac Amyloid

Four distinct antibody-based strategies are represented in the retrieved patent and literature dataset, each targeting a different point in the amyloid deposition cascade — from direct fibril binding to upstream plasma cell depletion.

1. Anti-Amyloid Fibril Monoclonal Antibodies

This is the most patent-active modality. Conformation-specific antibodies bind cross-β-sheet epitopes exposed on fibrils but not on native soluble proteins, promoting Fc receptor-mediated phagocytic clearance by macrophages and myeloid cells. Two candidates dominate the dataset. NEOD001 (birtamimab), developed by Prothena Biosciences, is a humanized anti-light chain antibody (humanized form of murine antibody 2A4) that binds soluble and insoluble light chain aggregates and promotes phagocytic clearance. Prothena’s preclinical data showed that 2A4 specifically labeled 21 out of 21 fresh-frozen patient organ samples and induced phagocytosis of AL amyloid in vitro. Antibody 11-1F4 (cael-101), developed at Columbia University, targets amyloid fibril conformation and activates immune clearance, with patent claims citing the ability to improve myocardial function within three weeks of treatment and NYHA functional class shift from III to I.

2. SAP Depletion + Anti-SAP Antibody (Dezamizumab/Miridesap)

This two-component strategy, developed at University College London in collaboration with GlaxoSmithKline, involves first depleting circulating SAP using the small molecule CPHPC (miridesap) to render SAP in amyloid deposits antigenically exposed, then administering the anti-SAP monoclonal antibody dezamizumab to direct macrophage-mediated phagocytosis to the amyloid deposit. Preclinical work in transgenic mouse models showed swift, almost complete clearance of visceral amyloid. A Phase 2 open-label study in cardiac amyloidosis patients (n=7) provided pharmacodynamic evidence of dezamizumab cardiac uptake confirmed by immuno-PET imaging — the most advanced direct clinical evidence for antibody-mediated clearance specifically in cardiac amyloidosis in this dataset.

“SAP-targeted clearance remains the only approach with clinical Phase 2 cardiac-specific evidence in this dataset — with immuno-PET confirming that dezamizumab reaches cardiac amyloid deposits in living patients.”

3. Anti-CD38 Monoclonal Antibody (Daratumumab) — Upstream Clone Depletion

Daratumumab targets CD38, a cell surface antigen highly expressed on plasma cells responsible for producing amyloidogenic light chains in AL amyloidosis. Its mechanism is upstream — plasma cell depletion rather than direct fibril clearance — but its downstream impact on cardiac biomarkers is clinically meaningful. The ANDROMEDA Phase 3 trial demonstrated that D-VCd (daratumumab plus bortezomib, cyclophosphamide, and dexamethasone) produced improved cardiac response rates across Mayo Stages I through IIIA. The University of Turin notes that CD38 is an ideal target given the small, indolent nature of AL plasma cell clones. A Tufts Medical Center patent discloses dual-antibody combination methods pairing NEOD001 with daratumumab, reporting NT-proBNP cardiac response data — addressing both ongoing fibril production and established cardiac burden simultaneously.

4. TTR Silencing and Stabilization (Contextual Comparators)

For ATTR-CM, gene-silencing strategies — patisiran, vutrisiran (siRNA), inotersen, and eplontersen (ASO) — target hepatic TTR mRNA to reduce circulating TTR protein supply, suppressing new fibril formation but not addressing established deposits. TTR stabilizers including tafamidis, acoramidis, tolcapone, and diflunisal prevent tetramer dissociation into amyloidogenic monomers. A review from the University of Ferrara explicitly categorizes “destruction and re-absorption of already formed amyloid tissue deposits” as a third mechanistic pillar of ATTR-CM therapy, with antibodies described as still at Phase 1–2 as of 2022 — the gap that fibril-clearance antibodies are designed to fill. As noted by FDA regulatory frameworks, combination approaches that address both disease production and established burden represent an emerging trial design paradigm.

Who Owns the IP: Assignee and Patent Landscape

Patent activity in the ATTR cardiac amyloidosis antibody depletion space is concentrated among a small number of commercial and academic assignees, with Columbia University holding the dominant multi-jurisdictional position for direct fibril clearance antibodies.

Prothena Biosciences Limited holds multiple IL-jurisdiction pending patent filings (2021 and 2023) covering methods of treating AL amyloidosis with conformation-specific anti-light chain antibodies, with specific cardiac endpoint claims including NT-proBNP reduction thresholds and cardiac response rates in Mayo Stage IV patients. Tufts Medical Center, Inc. files IP covering the dual-antibody combination of NEOD001 plus daratumumab in AL amyloidosis, including cardiac response biomarker data, filed in SG jurisdiction in 2021. The University of Tennessee Research Foundation holds older AU patents (2003 and 2008) covering foundational anti-amyloid antibody removal methods — now inactive — reflecting early academic IP activity in this space.

The geographic spread of Columbia University’s portfolio — US, WO, AU, IL, IN, and CA — means that any commercial partner, licensee, or competitor developing antibody-based amyloid clearance for cardiac indications must conduct thorough Freedom-to-Operate analysis against the 11-1F4 portfolio. Patent prosecution remains active, with the most recent CA filings dated 2025. According to WIPO, multi-jurisdictional patent prosecution of this kind typically signals commercial intent and active licensing activity in the relevant technology area.

Clinical Signals and Proof That Cardiac Remodeling Is Achievable

The most important translational question in the ATTR cardiac amyloidosis antibody depletion field is whether clearing amyloid from the myocardium can produce measurable structural cardiac improvement — and the retrieved dataset provides several converging lines of evidence that it can.

Dezamizumab Phase 2 cardiac data — the GlaxoSmithKline-sponsored study (n=7, open-label) in cardiac amyloidosis patients using miridesap followed by dezamizumab reported pharmacokinetic, pharmacodynamic, and cardiac immuno-PET uptake data. This constitutes the most advanced direct clinical evidence for an antibody-mediated clearance strategy specifically in cardiac amyloidosis. The use of [89Zr]Zr-dezamizumab for immuno-PET imaging introduces a theranostic dimension — the same antibody platform used both to image amyloid burden and to direct therapeutic clearance — which may be differentiating for payer and regulatory positioning.

Columbia University 11-1F4 echocardiographic claims — patent claims include echocardiographic improvement within 3 weeks and NYHA functional class shift from III to I following administration of the chimeric 11-1F4 antibody, with echocardiogram data at week 0 and week 12 post-treatment referenced in patent figures. Prothena patent cardiac response thresholds — IL-jurisdiction filings specify that the cardiac response rate increases at least 30% after months of treatment in Mayo Stage IV AL patients, with NT-proBNP reduction of at least 60% from baseline after 6 months and an NT-proBNP nadir below 400 pg/mL after 3 months as defined response thresholds. Patients must have EF greater than 50% and 6-minute walk distance greater than 150 meters — criteria reflecting a clinically defined population likely drawn from or designed for clinical trial use.

The Amyloidosis Forum Cardiac Working Group — a public-private partnership between the Amyloidosis Research Consortium and the US FDA Center for Drug Evaluation and Research, launched in 2020 — is developing novel cardiac endpoints for clinical trials, signaling that regulatory infrastructure is being built to support antibody depletion trial design. This endpoint framework, referenced in the dataset, supports the use of imaging-based structural endpoints alongside NT-proBNP and troponin. Standards bodies including EMA have similarly emphasized the importance of patient-centered endpoints in rare cardiac disease trials.

“Sequential endomyocardial biopsies over 17 years documented reduction in biventricular wall thickness and NYHA class improvement from III to I — establishing that cardiac remodeling after amyloid clearance is not theoretical but histologically confirmed.”

Combination Strategies and Emerging Directions

The most structurally novel strategies in the dataset attempt to address both ongoing fibril production and established cardiac burden simultaneously — a mechanistic gap that single-agent approaches cannot resolve.

Dual Antibody: Anti-Fibril + Anti-CD38

Tufts Medical Center’s SG-jurisdiction patent (2021) claims methods for combining NEOD001 (amyloid fibril-directed) with daratumumab (CD38-directed) in AL amyloidosis. The rationale is simultaneous upstream plasma cell clone depletion and downstream fibril clearance. This approach addresses a mechanistic gap that single-agent strategies cannot resolve: patients who achieve hematologic response (plasma cell suppression) but retain persistent organ dysfunction from established amyloid deposits are a defined clinical population that the dual-antibody strategy targets directly.

Sequential SAP Depletion + Anti-SAP for ATTR

The miridesap/dezamizumab approach is specifically being evaluated in cardiac amyloidosis, including ATTR subtypes. The theranostic dimension — using [89Zr]Zr-dezamizumab for immuno-PET imaging to confirm cardiac uptake before and after therapeutic dosing — represents an emerging framework for confirming target engagement in cardiac tissue, which is otherwise inaccessible without biopsy.

Antibody + TTR Silencing: Conceptual Convergence

The University of Ferrara review explicitly categorizes amyloid resorption as a third mechanistic pillar of ATTR-CM therapy and notes that antibodies remain at Phase 1–2. The conceptual convergence is that TTR silencing (patisiran, vutrisiran, inotersen, eplontersen) suppresses new fibril substrate production, while antibody-based clearance targets existing deposits. Future combination regimens pairing upstream silencing or stabilization with downstream fibril clearance antibodies are signaled in the retrieved literature as a logical next step, though no patent data on this specific combination appears in the dataset.

Proteolysis Map-Informed Antibody Design

The Pavia group’s 2020 mass spectrometry proteolysis mapping of AL cardiac amyloid fibrils — identifying specific N- and C-terminal fragmentation sites — provides the first high-specificity map of proteolytic cleavage sites in natural AL cardiac amyloid. This data could inform next-generation antibody design targeting proteolytically exposed neoepitopes on fibril fragments, potentially offering improved fibril clearance efficacy against structurally resistant deposits. Antibody engineering strategies that recruit more effective effector mechanisms — complement activation or ADCC-optimized Fc variants — are identified as a translational priority given the structural resistance of AL cardiac fibrils.

CRISPR/Cas9 In Vivo Gene Editing

In vivo DNA editing of the TTR gene is mentioned in the Ferrara review alongside siRNA and ASO modalities as a potential future approach for ATTR-CM. No patent data on CRISPR for cardiac amyloidosis appears in the retrieved dataset, placing this firmly in the nascent/speculative category as of the dataset snapshot date.

Strategic Implications for Drug Developers and IP Teams

The retrieved dataset yields five strategic conclusions for teams working in the ATTR cardiac amyloidosis antibody depletion space.

• Cardiac remodeling is a quantifiable endpoint: The Sapienza University case report with sequential biopsy evidence and Columbia University echocardiographic patent claims establish that amyloid clearance can produce measurable structural cardiac remodeling — wall thickness reduction, diastolic function improvement, NYHA class improvement. Drug developers should incorporate imaging-based structural endpoints alongside NT-proBNP and troponin in trial designs, supported by the FDA-Amyloidosis Research Consortium endpoint framework.
• Columbia University holds a dominant multi-jurisdictional patent position: With active patents in US, AU, IL, and CA jurisdictions filed across 2019–2025, any commercial partner, licensee, or competitor developing antibody-based amyloid clearance for cardiac indications must conduct thorough Freedom-to-Operate analysis against the Columbia University 11-1F4 portfolio before advancing to clinical development.
• The NEOD001/daratumumab dual-antibody combination is IP-protected but underexplored: Tufts Medical Center’s SG-jurisdiction patent covering NEOD001 plus daratumumab addresses a mechanistic gap that single-agent approaches cannot resolve. IP strategists should monitor whether this approach proceeds to clinical validation and whether broader geographic filings follow.
• SAP-targeted clearance has unique Phase 2 cardiac-specific clinical evidence: The GlaxoSmithKline dezamizumab Phase 2 data in cardiac amyloidosis patients, while limited in scale (n=7), represents unique clinical proof that antibody-mediated amyloid clearance can reach cardiac tissue as confirmed by immuno-PET. The theranostic dimension is potentially differentiating for payer and regulatory positioning.
• Fibril structural resistance is a translational barrier requiring engineering solutions: Cryo-EM and mass spectrometry data from Heidelberg and Pavia respectively identify post-translational modifications and proteolytic cleavage patterns that make AL cardiac fibrils resistant to endogenous degradation. Antibody engineering strategies targeting neoepitopes from these modifications, or recruiting complement activation and ADCC-optimized Fc variants, may offer improved fibril clearance efficacy. This is a defined R&D gap that the PatSnap life sciences intelligence platform can help teams monitor through patent and literature surveillance.

The overall pattern in this dataset — commercial IP concentrated at Columbia University, Prothena, and Tufts; clinical translational evidence predominantly academic — is consistent with a field where fundamental IP has been filed and commercial entities are advancing toward clinical validation. Pipeline watchers should monitor Phase 2 data readouts, particularly for dezamizumab in cardiac ATTR and for any combination fibril-clearance trials that may emerge from the Tufts dual-antibody rationale. The PatSnap innovation intelligence platform tracks patent prosecution, clinical trial registrations, and literature signals across this space in real time.